Psychiatric Annals
September 1, 2022
Fernando Espí Forcén, Maren Nyer
To date, ketamine is the only prescribable psychedelic medicine in the United States. Ketamine is also one of the most promising drugs for the treatment of depression. In the current paradigm of care, most ketamine clinics in the United States treat patients with mood disorders with ketamine and its derivatives alone without psychotherapy. The purpose of this article is to review the most...
Neuropharmacology
September 1, 2022
Hao-Ming Hua, Chao Huang, Hanyu Liu et al.
35 citations
The discovery of the robust antidepressant actions of ketamine is regarded as one of the greatest advancements in depression treatment in the past 60 years. Recent findings have provided strong evidence for the presence of bidirectional communication networks between the gastrointestinal tract and the brain in depression. Moreover, increasing evidence supports the antidepressant role of...
Neuropsychopharmacology
September 1, 2022
Deepak Cyril D'Souza, Shariful A. Syed, L Taylor Flynn et al.
156 citations
There is considerable interest in the therapeutic potential of psychedelic drugs. Dimethyltryptamine (DMT) is a potent, rapid-onset, and short-acting psychedelic drug that has not yet been independently tested for the treatment of depression. The safety, tolerability, and efficacy of intravenous DMT were investigated in treatment-resistant individuals with major depressive disorder (MDD) and...
BJPsych Open
September 1, 2022
Tommaso Barba, Sarah Buehler, Hannes Kettner et al.
57 citations
Background Major depressive disorder is often associated with maladaptive coping strategies, including rumination and thought suppression. Aims To assess the comparative effect of the selective serotonin reuptake inhibitor escitalopram, and the serotonergic psychedelic psilocybin (COMP360), on rumination and thought suppression in major depressive disorder. Method Based on data derived from a...
Addictive Behaviors
September 1, 2022
Kevin H. Yang, Benjamin H Han, Joseph J Palamar
30 citations
There is renewed interest in the clinical application of hallucinogenic substances to treat a range of psychiatric conditions. However, there is mixed evidence regarding how use of such substances outside of medical settings relates to psychological distress, depression, and suicidality. We examined data from a US representative sample of noninstitutionalized adults from the 2015-2020 National...
International Journal of Public Health
August 25, 2022
L. Hou, Lei Chang, Li-Rong Chen et al.
Objectives: Previous studies revealed a positive association between neuroticism and depression. This study further extended the previous findings by exploring the psychological processes underlying this association among Chinese postgraduates. Guided by theoretical models and empirical research, we proposed a multiple mediation and moderated mediation model to investigate the roles of...
Journal of High School Science
August 25, 2022
Zoe Graham
Depression is a devastating disease, affecting hundreds of millions of people worldwide. Cases of difficult-to-treat depression are also increasingly common, exposing the ineffectiveness of currently available treatments. This paper reviews evidence supporting the use of psilocybin, the prodrug found in psychedelic mushrooms, as a potential antidepressant for treatment-resistant and...
August 22, 2022
John M. Pederson, Kathryn Cowie, Averi Barrett et al.
BACKGROUND Psilocybin is a naturally occurring psychedelic that induces feelings of euphoria and spiritual awakening when administered in doses of approximately 20-30 mg/70 kg. In the last decade, there has been renewed interest in using psilocybin for major depressive disorder (MDD). OBJECTIVE This individual patient data meta-analysis will investigate the efficacy and safety of psilocybin for...
Frontiers in Psychology
August 18, 2022
Hui-Rong Guo, Jun-Ru Wang, Ya-Li Wang et al.
ObjectiveThis study aims to investigate the effectiveness of mindfulness-based cognitive therapy (MBCT) combined with medication therapy in preventing the recurrence of major depressive disorder (MDD) in convalescent patients.MethodsA total of 130 patients with convalescent MDD were enrolled in this prospective study. Sixty-five patients were assigned to the experimental group and received...
Expert Opinion on Investigational Drugs
August 17, 2022
Bartłomiej Pochwat, A. Krupa, M. Siwek et al.
ABSTRACT Introduction Pharmacotherapy of depression is characterized by the delayed onset of action, chronic treatment requirements, and insufficient effectiveness. Ketamine, with its rapid action and long-lasting effects, represents a breakthrough in the modern pharmacotherapy of depression. Areas covered The current review summarizes the latest findings on the mechanism of the antidepressant...